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Molecular imaging can potentially provide means for mon-
itoring response to therapy in rheumatoid arthritis (RA) early
in the course of disease [1].Quantitative measurements of
RA disease activity made in the wrist by whole-body PET
scanners, however, have inadequate accuracy because of
limited spatial resolution [2]. A high-resolution PET/CT
scanner for imaging extremities has been built at our insti-
tution [3]. In conjunction with a clinical MRI scanner, high-
resolution PET/MR images can be obtained for the wrist.
The CT image is used for PET/MR image coregistration.
A 57-year-old female with established RAwas stable until
a recent clinical flare-up in the right wrist. Clinical exami-
nation revealed synovitis, swelling, and diminished range of
motion. The patient also had a history of osteoarthritis (OA).
An extremity
18F-FDG PET/CT scan immediately following
MRI at baseline was performed on this patient. Tumor
necrosis factor alpha (TNF-α) inhibitor (etanercept) therapy
was then initiated as a part of the patient’s standard of care.
The patient was re-scanned 5 weeks after starting treatment.
The figure shows high-resolution
18F-FDG PET images
(pseudocolor) overlaid on pre-contrast MRI images (gray
scale) at baseline (left column) and 5 weeks (right column).
Significant reduction in PET signal (suggesting reduced
inflammation) in the synovium and at sites of erosions (white
arrows) is visible. The green arrow shows inflammation due
to OA. Physician examination at 3 months confirmed that
this patient responded positively to etanercept. This case
illustrates the potential of high-resolution PET with MRI for
quantitative visualization of early response to therapy in RA.
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